Puridify named as finalist for two prestigious bioprocess industry awards

Industry evaluations demonstrate single-use mAb purification technology offers significant productivity gains

London, UK – 30 September 2016 – Puridify Limited ("Puridify"), developers of novel bioprocessing purification technologies for industrial biomolecule manufacture, has been announced as a finalist for two BioProcess International Awards. These prestigious industry awards recognize the outstanding people, organizations, and technologies that define excellence and that have changed the status-quo by enabling more effective, less expensive biotherapeutic development and manufacturing.

The two awards for which Puridify has been shortlisted are:

Best Downstream Technology Application - for Puridify's FibroSelect™ nanofiber single-use purification technology.

Best Collaboration - with GlaxoSmithKline to advance industrial evaluation of Puridify's FibroSelect.

Oliver Hardick, CEO of Puridify commented: "Being nominated for these two awards, which puts Puridify alongside the likes of Pall Corporation and Sanofi-Genzyme, is an incredible honour and testament to the hard work and excellence of our R&D team. Our platform continues to demonstrate enormous relevance and value to the process development community, and industrial support from leading biopharmaceutical companies across Europe and the USA is helping us move towards commercial manufacture of the FibroSelect™ technology. The willingness to engage gives us confidence in the industry's readiness to adopt novel technologies that make significant productivity gains and reduce process development times, which will ultimately deliver benefits to patients."

The full details of the nominations can be found at:

Best Downstream Technology Application - http://www.bioprocessintl.com/bioprocess-international-2016-awards/best-collaboration-2016-bioprocess-international-awards/

Best Collaboration - http://www.bioprocessintl.com/bioprocess-international-2016-awards/best-technology-application-downstream-finalists/

Dr Hardick will present data on the development, scale-up and industrial evaluation of Puridify's FibroSelect single-use purification technology at this year's BPI conference. The presentation will include data from industrial evaluations (at 50L batch scale) showing FibroSelect can offer at least 40x higher productivity compared to traditional packed columns, whilst maintaining critical quality attributes.

Details of the presentation are as follows: "*Single-Use Primary Capture Technology with the Promise to Deliver New Standards for the Economics, Convenience and Reliability of mAb Bioprocessing*", in the session "*Recovery and Purification, - Future Technologies and Their Impact on Downstream Processing*", 10.30am, Wednesday 5th October.

- END -

Notes to Editors

BPI Awards
Judged by a distinguished panel of independent biopharmaceutical experts, and supported by bioprocess specialist publication *BioProcess International*, the awards ceremony takes place during the BioProcess International Conference on the evening of Wednesday, 5 October 2016.

About Puridify Ltd
Puridify Limited is a UK-based bioprocessing company with a platform purification technology, FibroSelect, which enables new processing strategies aimed at significantly reducing the cost and time associated with manufacture. The company is funded by leading venture capital investors Imperial Innovations and SR One who recognised the significant value that Fibroselect™ can release to a large and growing marketplace that is seeking efficiency but which has seen little in the way of innovation. Puridify's head office and research & development facilities are based at the Stevenage Bioscience

Catalyst. The company works closely with industry experts and leading industrial collaborators from around the world, to drive the rapid development of its platform technologies.

Puridify has secured a number of prestigious awards, including the SR One funded OneStart Competition and Innovate UK Proof of Concept Bid to Smart Award in 2013; Innovate UK's Feasibility Studies and Collaborative R&D Awards in 2014; and this year received an Innovate UK Industrial Biotechnology Catalyst Project award, co-funded by the Engineering and Physical Sciences Research Council (EPSRC) and the Biotechnology and Biological Sciences Research Council (BBSRC).

For more information, visit www.puridify.com

Biotherapeutic Industry Context

Global demand for cheaper biotherapeutics, such as antibodies and vaccines, and the growth of biosimilars, which represent many of the new tools in the fight against diseases such as cancer, inflammation and neurodegenerative conditions, is driving the need for increased efficiency in biomolecule manufacturing. A significant proportion of current costs arise from the purification technologies now used to ensure the safety and efficacy of these treatments. Recent rapid evolution of the global biopharmaceutical market has drawn focus to the limitations of current purification operations, demanding a step-change improvement in processes. The rapid development of "Next Generation" biotherapeutics of increased complexity and size in addition to a focus on process efficiency, flexibility and convenience during manufacturing is driving the need for innovative but robust technologies that enable new platform processing strategies.

About Fibroselect

Puridify has leveraged proprietary technology with industrial expertise to develop industry-ready products that will bring significant simplification and performance benefits to downstream processing of biotherapeutics. The unique high capacity (Dynamic Binding Capacities comparable to packed beds) combined with high flowrate properties (3 minute chromatography runs, 1 second residence times) of FibroSelect™ enables the replacement of columns that are >50x larger. This is achieved by using a 'multi-cycle, single batch' mode of operation that greatly improves productivity allowing the operation to be shrunk to the point that single-use operation is economically viable. These highly cost effective, ready to use, units will reduce validation burden, improve process robustness and increase facility flexibility.

FibroSelect™ simplifies chromatography so that it can behave in a way akin to adsorptive depth filters whilst maintaining compatibility with existing facility infrastructure. Making use of well understood materials such as cellulose also allows a broad scope of current ligands such as Protein A to be used with FibroSelect as a solution in costly product-capture applications. The performance and operating characteristics offer highly desirable rapid process development opportunities valued by the biopharmaceutical industry.

For more information, please contact:

Dr Oliver Hardick, Chief Executive Officer
Puridify Ltd
E: info@puridify.com

Media enquiries to Instinctif Partners
Dr Lynne Trowbridge, Tim Watson, Priya Kalia, Alex Bannister
T: +44 20 7866 2825
E: puridify@instinctif.com